患有左心室辅助器件的患者的SGLT2抑制剂和心血管结果
Hoang Nhat Pham1, Ramzi Ibrahim2, Xuan Ci Mee2
1Department of Medicine, University of Arizona-Tucson, Tucson, AZ, USA; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Journal of cardiology
|May 24, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂改善了左心室辅助器件 (LVAD) 患者的生存率和减少住院病例. 这表明SGLT2抑制剂可能是LVADs高级心力衰竭患者的有益辅助疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗器械 医疗器械
背景情况:
- 左心室辅助器件 (LVAD) 对晚期心力衰竭 (HF) 至关重要,但面临并发症和结果的挑战.
- -葡萄糖共运输体2 (SGLT2) 抑制剂在高血压中表现有前途,但它们对LVAD患者的影响尚不清楚.
研究的目的:
- 评估SGLT2抑制剂使用与LVAD患者的临床结果之间的关联.
- 评估SGLT2抑制剂对LVAD患者心脏移植率的影响.
主要方法:
- 使用TriNetX网络进行的回顾性队列研究 (2014-2022年).
- 确定了成年LVAD患者,分为SGLT2抑制剂使用者和非使用者.
- 倾向性得分匹配 (1:1) 平衡的基线特征;分析死亡率,住院,HF恶化,主要不良事件和安全结果.
主要成果:
- 使用SGLT2抑制剂与所有原因死亡率,住院,HF恶化,脑梗塞和心脏骤停的风险显著降低.
- 没有观察到心脏移植率或急性心肌梗塞的显著差异.
- SGLT2 抑制剂显示出有利的安全性概况,急性损伤 (AKI) 风险降低,尿路感染或泌尿器官候群症没有显著增加.
结论:
- 在LVAD患者中使用SGLT2抑制剂与改善生存率,减少住院和减少心力衰竭恶化有关.
- 他们注意到了有利的安全结果,包括较低的AKI风险.
- 这些发现支持进一步研究SGLT2抑制剂作为LVAD患者的辅助疗法.
相关概念视频
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
943
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
943
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
01:22Heart Failure Drugs: β-Blockers
778
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
778
01:22Heart Failure VI: Adjunct Therapies
263
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
263
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K